Lynda Chin height - How tall is Lynda Chin?

Lynda Chin was born on 2 January, 1968 in China, is a Chinese-American medical doctor. At 52 years old, Lynda Chin height not available right now. We will update Lynda Chin's height soon as possible.

Now We discover Lynda Chin's Biography, Age, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is She in this year and how She spends money? Also learn how She earned most of net worth at the age of 52 years old?

Popular As Lynda Chin
Occupation N/A
Age 52 years old
Zodiac Sign Capricorn
Born 2 January 1968
Birthday 2 January
Birthplace China
Nationality China

We recommend you to check the complete list of Famous People born on 2 January. She is a member of famous Doctor with the age 52 years old group.

Lynda Chin Weight & Measurements

Physical Status
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Who Is Lynda Chin's Husband?

Her husband is Ronald DePinho

Parents Not Available
Husband Ronald DePinho
Sibling Not Available
Children 3

Lynda Chin Net Worth

She net worth has been growing significantly in 2018-19. So, how much is Lynda Chin worth at the age of 52 years old? Lynda Chin’s income source is mostly from being a successful Doctor. She is from China. We have estimated Lynda Chin's net worth, money, salary, income, and assets.

Net Worth in 2020 $1 Million - $5 Million
Salary in 2019 Under Review
Net Worth in 2019 Pending
Salary in 2019 Under Review
House Not Available
Cars Not Available
Source of Income Doctor

Lynda Chin Social Network

Twitter Lynda Chin Twitter
Wikipedia Lynda Chin Wikipedia



Chin was a Senior Associate Member of the Broad Institute, where she became the principal researcher of the Genome Data Analysis Center in The Cancer Genome Atlas (TCGA). Chin was then elected scientific director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute. Chin was a co-leader of the Dana-Farber/Harvard Cancer Center’s Melanoma Program and the Specialized Programs of Research Excellence (SPORE) grant for skin research.


She is a recipient of the 2014 Lila and Murray Gruber Memorial Cancer Research Award.


In 2012, Chin was involved in controversial grant award by the Cancer Prevention and Research Institute of Texas (CPRIT). A Houston Chronicle investigation suggests that CPRIT her application for the approximately $18 million grant had been handled in a hasty manner designed to circumvent its own scientific reviewers.


Chin joined the University of Texas MD Anderson Cancer Center in 2011 as chair of first-ever Department of Genomic Medicine and scientific director of the Institute for Applied Cancer Science. She assists the scientific steering committee of the International Cancer Genome Consortium.


In 2002, Chin co-founded a cancer biotechnology company called AVEO Pharmaceuticals. 5 years later, Chin founded Metamark Genetics, a cancer diagnostic company dedicated to the development of prognostic and predictive cancer tests.


Chin has been a member of the Dana-Farber Cancer Institute's Department of Medical Oncology since 1999.


When she was 15, Chin and her family migrated from China to the United States. She then attended Franklin D. Roosevelt High School where 1984, she was valedictorian of her class. In 1988, Chin graduated from Brown University, receiving magna cum laude honors for her B.S in neuroscience. She earned her medical degree from Albert Einstein College of Medicine in 1993. Afterward, she began her postgraduate clinical and scientific training at New York–Presbyterian Hospital in New York City. From 1994-1997, Chin completed her research fellowship from Albert Einstein College of Medicine where she was also chief resident of dermatology.


Lynda Chin (born 1968) is a Chinese-American medical doctor. She is a board-certified dermatologist who was the founding department chair and professor of genomic medicine at the University of Texas MD Anderson Cancer Center, as well as scientific director of the MD Anderson Institute for Applied Cancer Science. In late 2012 she was elected as a member of the Institute of Medicine (IOM) of the National Academies.